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Abstract
This review reports on proceedings of a bone histomorphometry session conducted at the Fortieth
International IBMS Sun Valley Skeletal Tissue Biology Workshop held on August 1, 2010. The
session was prompted by recent technical problems encountered in conducting histomorphometry
on bone biopsies from humans and animals treated with anti-remodeling agents such as
bisphosphonates and RANKL antibodies. These agents reduce remodeling substantially, and thus
cause problems in calculating bone remodeling dynamics using in vivo fluorochrome labeling.
The tissue specimens often contain few or no fluorochrome labels, and thus create statistical and
other problems in analyzing variables such as mineral apposition rates, mineralizing surface and
bone formation rates. The conference attendees discussed these problems and their resolutions,
and the proceedings reported here summarize their discussions and recommendations.
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Introduction
The understanding of bone physiology accelerated in the 1950s with the development of
plastic-embedding technology for microscopic examination of undemineralized sections of
bone tissue. Prior to then, bone histology required removal of its principal component, the
mineral. This new technology was refined in several labs, in particular, the Radiobiology
Lab at the University of Utah in studies of the skeletal effects of plutonium and radium,
alpha radiation-emitting, bone-seeking metals. A benchmark occurred in 1960 with a
publication by Frost [1] entitled, “Measurement of Bone Formation in a 57 Year-old Man by
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Means of Tetracyclines.” This opened the door for study of the complete composite of
human bone, including both mineral and organic matrix. In 1983, a text was produced [2]
which summarized the methodology and stereological theories behind the
histomorphometric calculations. Another benchmark occurred in 1987 when the
nomenclature, symbols and units for bone histomorphometry were standardized [3]. As a
consequence, the use of in-life dual fluorochrome labels in humans and animals together
with the application of bone histomorphometric techniques has become a standard method
for studying the tissue level activities of bone modeling and remodeling. Starting in the late
1960s, Professor Webster Jee began the Sun Valley Workshops on musculoskeletal biology
that continue to the present. In August 2010, the International Bone and Mineral Society,
along with the National Institutes of Health, sponsored the 40th Annual IBMS/Sun Valley
Workshop on musculoskeletal biology. At that meeting a half-day session was devoted to
discussing issues in modern histomorphometry, 50 years after its introduction. The authors
participated in the presentations and subsequent discussion.
Change in landscape
The success of potent anti-remodeling agents in reducing fracture risk in osteoporotic
patients in recent years has presented new real world problems for bone histomorphometry,
as it is applied to explain their tissue level mechanisms. Bone biopsies taken from patients,
or specimens taken from animals treated with these agents, may have few or no
fluorochrome labels, creating difficulty in the interpretation of the dynamic
histomorphometric data and evaluation of patients’ or animals’ bone remodeling status. This
experience has generated a number of important questions that have been debated in
publications and scientific meetings over the past decade. Other issues involve use of proper
referents for histomorphometric measurements, clarification of the utility of certain bone
histomorphometric measurements and endpoints, sample size requirements for valid
measurements, quantification of rare events, and the variables that should be reported to
describe best the status of bone remodeling. The August 2010 Symposium sought to
summarize the following questions and provide recommendations on how they might be
answered:
1. How should one express and interpret mineralizing surface (MS/BS) and bone
formation rate (BFR/BS) in the absence or paucity of double and/or single label in
the standard sampling area?
2. How should mineral apposition rate (MAR) be expressed in the absence or paucity
of double label in the standard sampling area? Should MAR be imputed (i.e.,
assigned a value)? If so, when?
3. Is an “extended label search” worth doing in the absence of label in the standard
sampling area? (The definition of standard sampling area is 2–4 sections, ~100 μ
apart, from the middle one third of a human transiliac biopsy specimen, or
embedded animal specimen, sufficient to provide the minimum area for analysis as
described later.) What should be the purpose of such a search? If label is found
during the search, how should it be expressed?
4. Should MAR be measured and reported if found only on an extended label search?
If so, in what manner?
5. What is the minimum and practical maximum number of double label width
measurements required to achieve a reliable estimate of MAR? How should one
handle situations with insufficient double label to achieve a reliable estimate of
MAR?
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6. What is the minimum number of measured sections, area, and perimeter to provide
an adequate sample?
7. What is activation frequency? How should one interpret activation frequency?
What assumptions are required? Is it a valid expression of remodeling rate?
8. Can one measure “erosion depth” reliably? Is it valuable to do so?
9. Is the “obliquity correction” required for width measurements?
10. Should one examine cortical bone in human transilial biopsies? If so, what
variables should be measured?
11. What is the confidence in extrapolations from a transiliac biopsy (~1/14,000 of the
skeleton) to the entire skeleton?
12. Can one define the term “bone anabolic agent” solely in histomorphometric terms?
If not, what additional data are needed?
13. What is the definition of “over-suppression” of remodeling? Does “over-
suppression of remodeling” exist in a practical sense? Do biochemical markers of
bone formation and resorption assist in defining “over-suppression?”
Issues of measurement in low remodeling states
In bone biopsies that show few or no tetracycline labels after a standard in-life labeling
protocol [4,5], a number of related questions emerge pertaining to handling the data. These
are particularly important in human clinical studies that use iliac histomorphometry to
understand a disease condition or the tissue level mechanisms by which a drug is acting by
analyzing and comparing data from groups of subjects. The same questions apply to the
evaluation of bone in animals treated with these types of agents in pharmacology studies.
Forming surface
In vivo fluorochrome labeling to mark bone formation surface is done by the administration
of two time-separated (by ~14–17 days in humans, 10–14 days in large animals, or 2–7 days
in small animals) sequences of label shortly before obtaining the bone specimen. Thus, in
fluorochrome-labeled trabecular bone in human transilial biopsies, the overall forming
surface is defined as including both singly and doubly labeled surfaces. Because of the
“label escape” phenomenon [6,7], the most accurate measure of forming surface,
mineralizing surface (MS/BS), includes the combination of doubly labeled perimeter plus
half the singly labeled perimeter as a fraction (or percent) of the total trabecular perimeter,
i.e., MS/BS=100*(dL.Pm+(0.5*sL.Pm))/B.Pm (Table 2). MS/BS is the best expression of
the extent of surface remodeling in any specimen. This important variable is then used to
calculate a number of derived variables that express bone remodeling rates.
Three types of problems arise when labels of either type (double or single) are scarce or
absent in the standard analysis region, something that has been repeatedly encountered
during the study of anti-remodeling agents:
1. By examining the MS/BS formula, it can be appreciated that specimens that have
neither double nor single label in the standard analysis region have MS/BS of zero,
leading directly to an implied bone formation rate (BFR/BS) of zero (Table 2).
Specimens that have double label, but lack single label present no problem.
2. Other specimens that have only single label in the standard analysis region will
have non-zero MS/BS, but a non-calculable bone formation rate because mineral
apposition rate (MAR) cannot be calculated due to the absence of double labels.
Without double labels to measure, zero appears in the denominator (N, number of
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measurements taken) of the MAR formula, and in the denominator of the derived
variables in which it appears.
3. Still other specimens have so little double label in the standard analysis region that
they provide an insufficient sample for reliable assessment of MAR. These have
both non-zero MS/BS and nonzero bone formation rates, but lack reliability due to
an inadequate number of double labels available to sample for MAR.
In analyzing central trends and treatment effects in groups of patients, experience has shown
that the method of handling specimens with no or insufficient label in the standard analysis
region can produce significant bias in the analyses. Clearly, if specimens with no label in the
standard analysis region are simply treated as “missing data” and excluded from their
groups’ analyses, the result is an unacceptable bias toward overestimating remodeling rates
in the group. If specimens with insufficient label in the standard analysis region (see sections
on Change in landscape and Extended label search) are given the same weight as those with
adequate amounts of label, the result is an unacceptable reliance on poor data. Our
recommendations regarding the calculation of variables expressing bone formation rate
when double label is absent in the standard analysis region follow:
For the simpler variable, MS/BS, we recommend that the actual value always be reported.
Reporting “zero” for MS/BS when no label of any type is found is proper because it
accurately reflects the observations in the specimen. Reporting the actual value for MS/BS
when only single label is found, is proper because it again accurately reflects the data of the
specimen. Reporting the actual value for MS/BS when only one or two double labels are
found is proper because it not only reflects the specimen data accurately, but also has been
obtained on an adequate sample of bone perimeter.
For MAR, we recommend that the actual value be reported for a patient when it is non-zero
and sampling has been adequate (see subsequent discussion). We recommend that when no
label of any type is found in the standard analysis region, MAR should be reported as
“missing data” for that patient. It properly represents what was observed. There was no
double label upon which to base the calculation of MAR. We recommend that when only
single label is found in the standard analysis region, MAR be reported as “missing data” for
that patient. When only single label is found, it is also permissible to impute (assign) a value
for MAR (see Section Issues of measurement in low remodeling states). When an imputed
value for MAR is used calculations should be reported in both ways — one with MAR as
“missing data” and a second set using the imputed value of MAR. We recommend that when
insufficient double label perimeter is present for measuring MAR (see Section Extended
label search), the actual value for MAR is reported, but flagged as based on insufficient
double label evaluation and noted on the patient/animal report.
For the more complex variable, BFR/BS (Table 2), we recommend that the actual value be
reported for a patient when it is non-zero and sampling has been adequate for MAR (see
Section Extended label search). We recommend that when no label of any type is found in
the standard analysis region, a value of zero be reported for BFR/BS. While this ignores the
fact that MAR is reported as “missing data,” meaning that BFR/BS can technically not be
calculated, zero is a proper representation of the bone remodeling status, because the correct
interpretation of the histomorphometric finding is that the absence of label, providing a zero
MS/BS, overrides the technicality of not being able to calculate MAR. We recommend that
when only single label is found in the standard analysis region, BFR/BS be reported as
“missing data” for that patient. First, the patient’s status will be properly represented in the
MS/BS analysis. Second, because MAR cannot be calculated due to the lack of double label,
that is actually what was observed. As for MAR, it is also permissible to calculate BFR/BS
using an imputed value for MAR. When an imputed value for MAR is used, calculation of
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BFR/BS should be reported in both ways — one with BFR/BS as “missing data,” and a
second set using the imputed value of MAR to calculate BFR/BS. We recommend that when
insufficient double labeled surface is present, the actual value for BFR/BS is reported, but
flagged as based on insufficient double label evaluation and noted on the patient/animal
report.
Extended label search
When no double label, or insufficient double label from which to make MAR measurements
(see Section Extended label search) is found in the standard analysis regions, we recommend
that a limited extended label search be undertaken to confirm the presence or absence of
double label in the specimen, or identify additional double labels to solidify the
measurement of MAR. The most important reason to conduct any form of extended label
search is that when label is found outside the standard analysis regions, it can be confirmed
that the subject complied with the labeling schedule. When an extended label search is
undertaken, this should be noted on the patient’s report.
The first place to examine is the trabecular bone outside the standard analysis regions
defined as the area in sections outlined as in Fig. 1 to exclude the transitional zone and the
bone fragments on the marrow edges in the two unstained sections that were analyzed (see
Section Mineral apposition rate). If double label is found anywhere in this location, it can be
assured that the patient took the fluorochrome label as directed and that, in a
histomorphometric sense, some trabecular remodeling exists, despite the absence of double
label in the standard region for histomorphometric analysis. This label can be used to
solidify the measurement of MAR. The search is concluded.
If double label is not found as indicated earlier, the second place to examine is the cortices
of the two unstained sections that contain the standard analysis regions. If double label is
found in the cortices, it can be assured that the patient took both fluorochrome labels and has
cortical remodeling, but not that the subject has trabecular remodeling. Cortical double
labels cannot be used to solidify the measurement of MAR. It is just as certain that neither
this limited search, nor any rational histomorphometric search, can ever confirm the absence
of trabecular remodeling in the subject. In fact, experience has shown that most subjects,
who lack double label in any part of the trabecular region from the first two levels of
examination, have double label somewhere in the cortical region of those levels.
We believe that it is not warranted to continue to search for double labels in trabecular
regions past this point. The discussion pertaining to the normal lower limit of remodeling
provides a partial answer: total absence of double label anywhere in an iliac biopsy
specimen did not occur in the standard analysis region of biopsies from a sizable cohort of
normal premenopausal women in whom remodeling rates were quite low [8]. Thus, total
absence of label in a specimen in an extended label search appears to mean that the subject’s
remodeling rate is abnormally low, provided one is reasonably confident that the subject
complied with the labeling schedule. Again, it is the authors’ contention that no search of the
transilial biopsy specimen, including sectioning the specimen until exhaustion and
examining repeated trabecular regions in detail, can assure the absence of trabecular
remodeling. Our opinion is that it is certain that the finding of no double label in the
standard analysis region indicates the existence of a low remodeling condition. The practical
difference between this state and that indicated by sectioning a specimen until exhaustion
and finding no double label, is too small to be worth the additional work. This finding of low
remodeling is confirmed for a group when similar data emerge from multiple individuals
within a treatment group.
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However, if either single or double label is found outside the standard analysis region during
an extended label search, how does one express the result for purposes of analyzing data
from a cohort? In this case it is justified to use MAR calculated from trabeculae outside the
standard analysis region in calculation of those variables that use the value as long as this is
noted. Further, as noted earlier, standard histomorphometric report forms should include a
location that, in the event of a zero MS/BS, records that an extended label search was
performed and its outcome.
Although compliance with the labeling instructions can sometimes be confirmed by
collecting and analyzing urines for tetracycline at the time of labeling, there are practical
problems with this, including sample collection, shipping and analytical difficulties. We
recommend that a patient or research subject be contacted by telephone on the days when
fluorochrome label is to be consumed, to review specific details (i.e., timing of tablets; not
to be taken within 2 h of a meal; and not to be consumed with calcium supplements, dairy
products, or antacids in the surrounding 2 h) and obtain verification that the medication was
properly taken. We also recommend that the investigators should: a) limit the time the
specimen stays in aqueous fixative to 24 h, b) limit the exposure of the specimen and cut
sections to ambient light, and c) use appropriate UV light sources for fluorescence
microscopy. For animals, we recommend that fluorochrome label be given by subcutaneous,
rather than intraperitoneal (IP) injection. IP injections have the potential for injection into
the gut or bladder which will result in lack of incorporation.
Mineral apposition rate
The mineral apposition rate (MAR, μm/day) is the rate at which mineral accretion occurs at
a remodeling site during the period of bone formation. MAR is a fundamental
histomorphometric variable that is the second one included in the calculation of all dynamic
bone remodeling variables (i.e., bone formation rate, etc.) (Table 2). By itself, it is a reliable
measure of osteoblast function. Further, its value is quite robust since its range of values is
relatively small whenever its calculation is possible, provided there is no inhibition of
mineralization.
There are at least three situations when its expression is problematic, i.e., when double label
is absent in the standard analysis regions, but present on an extended label search; when
insufficient double label is present in the standard analysis regions to provide a reliable
assessment of MAR; and when double label is absent in both the standard analysis regions
and extended label search. In the first case, one can report finding it in the extended label
search, but regard it as missing data in the report, and derived variables should be reported
as zero (i.e., BFR/BS and others, including MS/BS). When too few double labels were
observed in the standard analysis region to provide reliable calculation of MAR, this should
be noted in the report (see section Change in landscape). However, this MAR should be used
in the calculation of derived variables. When no double label is found in either the standard
analysis region or on extended label search, we recommend that MAR should be reported as
missing data, and derived variables should be reported as zero.
Double label sites outside the standard analysis regions need not be added to the surface
measurements and calculation of MS/BS and/or derived variables. That would create the
impractical need to perform the entire set of static and dynamic histomorphometric
measurements in all the outside areas examined in order to calculate derived variables. This
would entail significant increases in time spent reading sections, and provide no useful
contribution to the understanding of remodeling status.
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Imputed value for MAR
When single label is present in the standard analysis region and no double label or an
unreliable amount of double label is found even on an extended label search, it is
permissible to use an imputed value for MAR of 0.3 μm/d, a figure reported as the lowest
value seen in a cohort of human biopsies [9]. We recommend that when one reports data that
uses an imputed value for MAR, one should report datasets both with and without the
subjects in whom an imputed value was used. One should be aware that assigning an
imputed value at the 5th percentile of published normal MAR values [9,10], 0.3 μm/d, to
any individual specimen in a group, creates a bias toward underestimating the true MAR and
BFR/BS for the group. On the other hand, if the absence of double label and MAR
measurements is simply treated as missing data, the group central trend is biased toward
overestimation.
Adequate sample of double label width measurements for estimating MAR
Inter-label width (iL.Wi) should be measured in any specimen that has trabecular double
label anywhere in the standard analysis regions. A guideline for the minimum distance
between measurement sites along a double label is ~20 μm, but the selection of that distance
is left to the individual investigator. Newer automatic histomorphometry software coupled
with digital scanners that perform automatic measurements at intervals as small as 1 μm are
useful advances. The number of measurements taken (N.iL.Wi) and the number of double
labels (N.dL) should be clearly recorded. In the reference cited earlier for healthy
premenopausal women [8], the 10th, median and 90th percentiles for numbers of
measurements of iL.Wi were 4.6, 20, and 38, respectively. Thus, our recommendation is that
when label is relatively scarce, a minimum of five measurements on a minimum of two
independent double labeled surfaces be obtained. When ample label is present, sampling
should be in the range of 20–40 measurements. Though all double labels should be
thoroughly sampled, it is never necessary to obtain more than 50 individual measurements
of iL.Wi to be used in the calculation of MAR. More than 50 measurements taken at 20 μm
intervals, does not result in significant change in the value (RR, unpublished data). When the
minimum of five is not met for a subject, that fact should be noted on the subject/animal’s
report. Many histomorphometrists now use newer image analysis systems that perform the
iL.Wi measurements automatically after the user outlines the borders of the area containing
the double labels. The computer software then makes a large number of width measurements
between the labels and expresses their average over all sites measured. The advantage with
these systems is that each double label site is sampled many more times than can be done
with older systems that require the reader to pick a small practical number of randomly
chosen sites on which to perform individual measurements of iL.Wi. The number and length
of the double label sites should be reported in order to estimate the adequacy of the sample
of iL.Wi measurements.
Adequate sampling of a human transilial biopsy (Fig. 1)
The minimum acceptable total section area (Tt.Ar) in the standard analysis regions is 30
mm2. The minimum acceptable total section perimeter (Tt.Pm) is 60 mm. The authors
recommend obtaining two sets of sections as a standard. The first set is taken from an area a
bit less than half way through the biopsy cylinder. The second is taken from an area ~300
μm further through the biopsy core. This leaves enough of the embedded block intact for
additional sectioning if needed or for application of other analytical techniques (e.g.,
backscattered electron imaging to assess mineralization density).
Each set consists of three sections, one for Goldner’s stain (Fig. 1), one for Toluidine blue
(or McNeal’s tetrachrome) stain and one left unstained for fluorescent microscopy. If the
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two levels do not provide standard analysis regions with at least 30 mm2 of total section area
(Tt.Ar) and 60 mm of total section perimeter (Tt.Pm), another set is taken ~300 μm further
through the specimen, and more measurements are added to the dataset for that specimen. It
is rare that an intact, well-fixed human iliac biopsy core taken with a 7.5 mm trephine
contains less than 30 mm2 in the standard analysis regions from two sets of sections.
Activation frequency and erosion depth: meaning and measurement
Bone remodeling or turnover is carried out by teams of juxtaposed osteoclasts (at the front)
and osteoblasts (bringing up the rear), comprising temporary anatomical structures known as
basic multicellular units (BMUs). In cortical bone, the BMUs drill tunnels or “cutting cones”
through the compact tissue while in spongy, cancellous bone, they usually gouge across the
trabecular surface forming a serpentine trench [11]. Bone turnover begins by conversion of a
quiescent skeletal surface to a remodeling site, a process referred to as activation. The
activation frequency (Ac.f) represents the probability (#/year) that a new remodeling cycle
will be initiated at any point on the cancellous perimeter and is calculated by dividing the
surface-based bone formation rate (BFR/BS) by the average amount of bone formed by a
team of osteoblasts per activation event, i.e., the wall thickness (W.Th). Thus, Ac.f=((BFR/
BS)/W.Th). The measurement is more than just the rate of BMU origination, as it
corresponds to the product of the frequency of BMU origination and completed bone
structural unit (BSU) thickness, rate of progression and lifespan. Ac.f is the best available
two-dimensional histologic index of the intensity of bone remodeling or turnover and as
such, also represents the number of BMUs currently active.
Ac.f is a highly derived variable whose determination presents issues in calculation (Table
2), assumptions, and interpretation. As discussed earlier, fluorescent labels are occasionally
missing. In addition, even without an increase in bone formation rate, Ac.f will increase if
W.Th decreases, as it does with age [12], and as it perhaps does with some anti-remodeling
therapies. If W.Th decreases without a change in BFR/BS, Ac.f could increase even though
the “rate of bone turnover” assessed by BFR/BS is apparently unchanged. Furthermore,
interpretation of the Ac.f becomes complicated when an anabolic therapy increases wall
thickness or thickens a trabecular profile by adding bone to a previously completed BSU, as
occurs with the intermittent administration of parathyroid hormone. Because the calculation
of Ac.f is based on measurements of MS/BS, it does not measure directly the activation of
osteoclasts, the vigor of their work, or their lifespan.
Some prefer using just MS/BS alone as a measure of the bone remodeling rate. However,
this approach has drawbacks: it is influenced greatly by the surface density and volume of
existing trabeculae, and does not take into account the length of time required to complete
the formation phase of remodeling sites. It is, however, a valid expression of remodeling
rates, and is correlated with remodeling as expressed by measurement of circulating
biochemical markers of bone formation and resorption [13]. As mentioned earlier, MS/BS is
also robust even in the face of absence of double and single label, as zero is a reasonable
value for MS/BS in such specimens.
While bone histomorphometric techniques work very well for the evaluation of bone
formation status, they are less reliable when used to evaluate bone resorption. Though the
concept of erosion depth is important and valid, there are multiple practical problems
associated with its measurement. Erosion depth represents an index of osteoclast vigor that
is otherwise difficult to determine. In theory, erosion cavities have an adverse effect on
cancellous bone strength disproportionate to the decrease in bone mass that the cavities
represent [14]. Furthermore, loss of bone strength due to perforation of trabecular profiles
becomes more likely as erosion depth increases. Erosion depth has a wide frequency of
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distribution. Limited evidence indicates that it decreases with age more noticeably in women
than in men [15]. Difficulty with the measurement itself occurs when erosion cavities have
unusual shapes that defy efforts to reconstruct the original bone perimeter [16]. In addition,
erosion cavities are often few and inconspicuous in specimens obtained from elderly patients
with osteoporosis. Selection of only the cavities ideal for measurement may cause
considerable measurement bias [17].
Eroded surface is a static measure that gives a valid snapshot of the morphologic picture of a
specimen’s resorption surfaces, but no direct information concerning the dynamic status of
resorption [13,18], because rate of osteoclast activity cannot be directly measured. The
eroded surface is composed of the osteoclast surface (about 1% of the trabecular bone
surface in humans) plus the reversal surface (about 9% of the trabecular bone surface in
humans). Osteoclast surface has proven useful in identifying the occasional occurrence of
large osteoclasts in persons treated with bisphosphonates [19,20]. Reversal surfaces increase
with defective or delayed bone formation, as occurs with glucocorticoid excess, and thus
may have little to do with the current amount of bone resorption. Moreover, most
antiresorptive drugs decrease the ability of osteoclasts to erode bone, reduce the BFR, and
actually increase the reversal surface, thereby, increasing eroded surface. Thus the
interpretation of eroded surface in cases in which anti-remodeling drugs have been used can
be misleading.
We recommend that osteoclast surface be included, because there is good inter-laboratory
consensus on its identification and it can provide valuable information on cell number. We
also recommend that despite limitations, eroded surface be included. While we acknowledge
the concept of erosion depth, we recommend that it not be evaluated in transilial biopsies
(Table 3), because the sample is usually small, the measurement can be quite variable, and
no inter-laboratory consensus on the optimal method for obtaining erosion depth data exists.
Histomorphometric variables (Tables 1–3)
The variables, and their symbols, included in Tables 1–3 are taken from the 1987 reference
that standardized the nomenclature, symbols and units for bone histomorphometry [3].
We recommend dividing histomorphometric variables into two classifications: measured
variables (Table 1) and variables that should be reported (Table 2) in all publication of
histomorphometric studies. However, the four cortical measurements can be omitted in any
report that does not require assessment of cortical remodeling. The reported variables
include a few measured variables used for quality assurance and a number of others that are
calculated by previously published formulae that are recorded here. Since microscope
variables refer to data that are collected from two-dimensional sections, they are always
expressed in two dimensions. Since reported variables nearly always refer to calculations
that are done to understand bone remodeling in a three-dimensional sense, they are
expressed in three dimensions (3D). We feel that the variables listed in Table 2 are
necessary and sufficient to show the complete picture of the histomorphometric findings in
any human or animal experiment.
The thickness expressions in the calculated trabecular variables are converted to 3D by
multiplying the width (microscope) measurements by π/4, the obliquity correction factor [3].
It is not necessary for cortical bone. Converting to 3D may aid in understanding the dynamic
(tetracycline-based) histomorphometric expressions of remodeling, and correlation with
non-histomorphometric measurements of dynamic bone remodeling and/or 3D
measurements of micro-architecture using μ CT may be improved [21]. We recommend that
authors indicate whether the obliquity correction factor was used in order to compare with
data from other reports.
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When widths (O.Wi, W.Wi, etc.) are measured at the microscope, it is important to report
the number of width measurements of each type to obtain an average value (i.e., N.O.Wi).
We consider the collection of some of the data in Table 1 optional and have so labeled them.
All variables in Table 2 should be included in reports and papers. As mentioned earlier,
when imputed MAR is applied for any member of a group, the group data should be
reported both with the imputed MAR data, and with MAR treated as missing data. The
cortical thickness measurements have gained in importance recently as investigators attempt
to understand the contribution of cortical bone to risk of fracture and the effect of
therapeutic agents that reduce remodeling and cortical porosity.
The variables in Table 3 can be calculated and may be reported. It is our experience that
these variables are problematic. In some cases, their measurement is difficult and has a
tendency to be biased. For cellular endpoints, inconsistent fixation may be a problem. In
other cases (Tb.Th, Tb.N, Tb.Sp), better methods for their measurement exist, such as
MicroCT, in which their values are calculated from 3D reconstructions. Fibrosis surface is a
good index, but is only relevant for a few conditions. The periods (F.P, R.P, and Rm.P) and
BFR/TV are heavily derived variables that have been of limited use in understanding how
drugs work to reduce fracture rate in osteoporosis.
There are numerous additional histomorphometric variables that could be named [3] and
added to Tables 1 and 2. However, the main use for histomorphometry is to understand the
status of bone remodeling and mineralization. The variables in Tables 1 and 2 are those that
are fundamental to that understanding, and thus justifying their inclusion.
Examples of measured variables used in other types of histomorphometric examinations
include: Number of osteocyte lacunae per unit B.Ar, number/fraction of osteocyte lacunae
containing normal osteocytes, number/fraction of osteocyte lacunae containing no
osteocytes; number/fraction of osteocyte lacunae containing apoptotic osteocytes, number/
fraction of osteocytes that are apoptotic, number of apoptotic osteoblasts/B.Pm, and area of
woven bone/B.Ar. The publication on nomenclature [3] suggests the possibility of numerous
useful calculated variables derived from the above microscope variables and others. We
recommend that when needed to suit a particular examination, histomorphometrists report
additional variables that are clearly-explained and appropriate for the purposes of the
specific investigation.
Application of bone histomorphometry to animal models
When properly used, animal models for bone research, most notably for pharmacology
studies, are considered among the most predictive models for human outcomes in any field
of pre-clinical pharmacology [22]. Adult rodents (mice and rats) and adult large animals
(e.g., non-human primates [NHPs: cynomolgus and rhesus], canines, sheep, etc.) are
differentiated by the fact that only cortical bone of adult large animals displays Haversian
remodeling like adult human cortical bone. Cortical bone of adult rodents has no ambient
Haversian bone remodeling. [23,24]. Thus, the adult rodent is best used only as a model of
trabecular bone remodeling.
Pre-necropsy dual fluorochrome labeling (subcutaneous calcein injection) with a five-to-
seven day interlabel time period for adult rats and a two-to-five day interlabel time period
for mice are routinely applied to produce double labels similar to those seen in humans. The
adult ovariectomized (OVX) rat [25] is commonly used in pre-clinical pharmacology
studies. Mice exhibit strain-related variation in bone behavior. They are widely-used today
to study variation in bone phenotype due to genetic alterations. Adult NHPs aged 10–12
years display estrogen-deficiency-induced bone loss and are used both to evaluate cortical
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bone remodeling and study bone responses in the typical human osteoporotic fracture sites.
Adult canines have appropriate trabecular and cortical bone remodeling, but do not display
reliable estrogen deficiency-related bone loss.
Most variables used in the analysis of trabecular bone in transilial bone biopsy specimens
from humans (Tables 1 and 2) not only can be measured/analyzed, but also have similar
meaning in adult rodents. The exception is W.Wi. Though it can be evaluated in adult rodent
vertebral trabecular bone, W.Wi cannot be readily measured in long bone metaphyseal
trabecular bone because of the paucity of completed bone structural units. Fortunately, an
excellent understanding of the effects of various agents (estrogens, bisphosphonates, PTH,
etc.) and physiologic conditions (e.g., skeletal unloading, vitamin D deficiency, etc.) can be
obtained in rodent experiments without evaluating W.Wi, by relying on MS/BS, BFR/BS,
and related variables. Eroded perimeter (E.Pm) is considered more difficult to identify in
rodents than in humans, making it less reliable than in humans. Therefore, osteoclast surface
(Oc.S/BS) is recommended as the best index of bone resorption in rodents. Reversal
perimeter, fibrosis perimeter, and erosion depth are generally not evaluated in rodents.
Mineralization lag time is much shorter in rodents than in humans, resulting in very thin
osteoid seams. Therefore, some variables such as osteoid thickness and volume are rarely
reported in rodent studies, unless an agent impairs bone mineralization and induces osteoid
accumulation. We recommend that MS/BS, MAR, and BFR/BS be handled as in humans
with one exception. When double fluorochrome label is absent, since the imputed value for
MAR (0.3 μm/day) discussed earlier was derived from human data; its use in animal studies
is not recommended. We recommend that imputed/assigned MAR values for rodents not be
used until an imputed MAR value derived specifically from rodents has been established.
The anatomical sites most frequently used for histomorphometric study in adult rats are the
proximal tibial and distal femoral metaphyses. When the metaphyses are too osteopenic,
something that is more likely to occur after ovariectomy and with advancing age, the lumbar
vertebral body can and should be substituted. The region of interest for histomorphometric
measurements intended to provide data that address adult human bone remodeling should
always exclude the primary spongiosa adjacent to the growth plate, which is composed of
newly-formed juvenile bone that compares poorly to adult human bone. The anatomical sites
most frequently used in adult mice to provide data about adult human bone remodeling are
the distal femoral metaphysis, proximal tibial metaphysis, and L1–L4 vertebral bodies. As
for rats, when the metaphyses are too osteopenic (e.g., after ovariectomy and in aged mice),
the lumbar vertebral body can be substituted. These sites are smaller, but generally more
uniform, than regions of the human transilial biopsy specimen. The minimum acceptable
Tt.Ar in rat trabecular bone is approximately 6–8 mm2, while the minimum acceptable B.Pm
is approximately 25 mm, both less than in the human. Histomorphometric measurements are
usually performed in two sections froma skeletal site separated by at least 50 μm. The
minimum acceptable Tt.Ar and B.Pm in mouse trabecular bone is approximately 60% of that
in rats, due to the smaller size of murine bones. Cortical bone studies in rodents are done in
cross-sections taken at either the mid-point of the femur or the region located 1–2 mm
proximal to the tibiofibular junction. These areas are used for the evaluation of periosteal
and endocortical surface endpoints. The internal cortex of rodents cannot be used for the
evaluation of Haversian remodeling. When conducting rodent experiments involving bone,
it is better to use large group sizes, rather than analyze more section area and perimeter
froma small number of animals. Although we recommend minimum group sizes of 6–8
rodents for bone histomorphometric studies as a starting point, it is best for group sizes in
individual experiments to be determined by a power analysis.
The anatomical sites most frequently evaluated in adult non-human primates (NHP) are the
typical human osteoporotic fracture sites, the vertebral body and the proximal femur. Since
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these sites can never be sampled systematically in experiments involving living humans,
most investigators feel that studying these sites leads to the most direct understanding of
how agents work at osteoporotic fracture sites in humans. The NHP iliumis also used for a
direct comparison to the usual sampling site in humans. The osteoporotic fracture sites in
NHPs yield enough trabecular bone that the minimums for sampling the human transilial
biopsy specimen apply. On the other hand, the NHP ilium generally yields a smaller
trabecular bone sample than the human transilial biopsy specimen. Its minimum acceptable
Tt.Ar is approximately 8 mm2, while its minimum acceptable B.Pm is approximately 25
mm. Multiple sections at 250 μm intervals should be studied to assure that these minimums
are met. Cortical bone studies of periosteal and endocortical surface endpoints in NHPs are
done using cross-sections taken at the seventh rib, the mid-point of the femur, the mid-point
of the femoral neck, and the center of the lumbar vertebral body. The interior of the cortex at
these sites is used to evaluate Haversian remodeling. When doing NHP experiments that
involve bone, the group size is often enlarged to accommodate mechanical testing of the
osteoporotic fracture sites, providing a generous sample size for histomorphometry.
Extrapolating data from a transilial biopsy specimen to the whole skeleton
The trabecular bone of the ilium is a red marrow site with a remodeling rate of ~10–15%/
year. When considering bone remodeling activity, it appears to be representative of similar
red marrow skeletal sites, such as the vertebral body [26]. It is not representative of fatty
marrow sites with their low remodeling rates. Its relationship to the proximal femur has not
been studied in any detail.
Transilial bone biopsies are not the best way to evaluate bone mass. While BV/TV in large
groups of individuals may actually give reasonable data and be useful in the experimental
setting, the small sample for analysis is a problem. DXA (dual energy X-ray absorptiometry)
and CT (computed tomography) not only sample much larger areas, but also work in the
osteoporotic fracture sites and are non-invasive.
We do not believe the Haversian portion of the cortical bone of a transilial biopsy specimen
can be sampled in a manner that allows calculation of reliable bone histomorphometric data,
because of the problems with consistent orientation during sectioning of the specimen. The
periosteal and endocortical surfaces of the two cortices are suitable for study, but tend to
provide limited perimeter. The data from each of the two cortices should be collected and
reported separately.
Defining “anabolic” in histomorphometric terms
Conceptually, bone anabolism requires a significant increase in bone mass that is driven by
an increased rate of formation of new bone unaccompanied by an offsetting increase in the
rate of bone resorption. This increase in bone mass can occur by formation activity at
trabecular, endocortical, or periosteal surfaces. For osteoporotic patients, the bone mass
increases should occur at the typical osteoporotic fracture sites, such as the spine, the hip,
and the wrist. It is noteworthy that this concept, and/or definition, of “bone anabolism” does
not apply in a growing animal model since bone anabolism occurs without any treatment
during growth.
In a technical sense, a bone anabolic agent is one that, in comparison to a baseline state or a
placebo group, increases bone mass by elevating the bone formation rate mainly through
increasing mineralizing surface and osteoblast number, rather than through increasing
activity of osteoblasts. Bone histomorphometric data are necessary, but not sufficient to
identify such agents properly. Likewise, non-invasive measurements of bone mass are
necessary, but not sufficient. The two types of measurements must be considered together.
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In humans, bone histomorphometric examination of transilial biopsies is the method of
choice for proving that bone formation has been stimulated. In small animals, sites such as
the proximal tibial metaphysis or vertebral body cancellous bone are studied. For both
animals and humans, increases in tissue level endpoints such as W.Th, MS/BS, OS/BS, and
BFR/BS form the cornerstone for recognizing higher levels of bone formation. They signal
the participation of increased numbers of osteoblasts and the existence of more sites of bone
formation. MAR only defines the status of osteoblast activity. Documenting higher MAR
alone is not sufficient to define anabolism. Mineralization status should remain normal in
the presence of an anabolic agent. Mineralization status is best defined by appropriate values
for variables data such as Mlt, Omt, and MS/OS. Increases in OS/BS must be accompanied
by appropriate increases in MS/BS. Biochemical markers of bone formation are often used
to confirm bone histomorphometric findings regarding bone formation status, but lack the
reliability to be used alone for this purpose.
The best way to measure anabolic change in bone mass is a non-invasive method that
samples large amounts of mineral, preferably at osteoporotic fracture sites. Bone
histomorphometry produces variables such as BV/TV and Ct.Ar that are indices of the bone
mass of the specimen itself. However, the specimen represents but a small sample of the
skeleton that may not reflect the status of osteoporotic fracture sites in humans or the spine
of experimental animals for bonemass purposes.
The best known methods for evaluating bone mass are DXA and CT. One or both should
always be applied in both human and animal experiments to determine bonemass, because
of their superior sampling ability, and, in humans, their ability to evaluate the osteoporotic
fracture sites and do repeat measurements.
Warning: pseudoanabolic agents
Frequently, agents display only one feature of the two required to define an anabolic agent.
Agents are known that cause rises in bone mass to occur in the absence of increased bone
formation rate. Others are known that induce bone formation rises without an accompanying
increase in bone mass. Neither type of agent is anabolic.
Anti-remodeling agents cause bone mass increases soon after they are begun. The rate of
initiation of new bone remodeling units declines to a new and lower level, while previously-
activated bone remodeling units finish their formation phases. Bone mass rises, due to
decreased bone resorption in the presence of bone formation rate sustained at its previous
rate, as the “remodeling space” is filled in. Bone formation rate eventually declines during
long-term administration of anti-remodeling agents, because the activation frequency of new
remodeling units has permanently declined. Examples include estrogens, bisphosphonates,
and anti-RANK Ligand antibodies. These are not anabolic agents.
Agents that stimulate remodeling raise bone formation rates soon after they are begun. Early
after the rate of initiation of new bone remodeling units rises, more are in the resorption
phase than are finishing the formation phase, actually creating bone loss. Bone mass
declines, due to a greater rate of bone remodeling that increases the amount of unfilled
“remodeling space.” Bone formation rate stays high and bone mass settles at a lower level
during long-term administration of remodeling stimulating agents because the remodeling
space is permanently enlarged. Examples include thyroxine and growth hormone. These are
not anabolic agents.
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Defining and detecting “oversuppression” of remodeling
The bone remodeling rate ordinarily remains within in a certain range that maintains health
of the skeleton. It is measurable by bone histomorphometric techniques and, to some degree,
by biochemical markers for formation and resorption. High remodeling rates, as in
postmenopausal women, patients with primary hyperthyroidism, and some cases of renal
osteodystrophy, cause bone loss, decreased bone strength, and increased fracture risk. These
elevated rates have been measured by both biochemical markers of formation and resorption
and bone histomorphometric techniques. The well-known age-related rise in fracture risk is
associated with increased remodeling as expressed by activation frequency, particularly
around menopause. It is, thus, not surprising that anti-remodeling agents work by a tissue-
level mechanism that decreases activation frequency, and reduces fracture risk.
Low bone remodeling rates represent the other side of that coin. It must also be remembered
that defining and detecting “oversuppression” of remodeling are two very different tasks. In
theory, oversuppression is defined as a condition (perhaps caused by a pharmacologic
intervention) that results in levels of remodeling activity low enough to cause harm to the
individual in the form of increased risk of fracture, much in the same way that high levels of
remodeling activity are associated with increased risk of fracture. Though speculation about
the existence of ultra-low remodeling rates that might be called oversuppression has
emerged recently, no skeletal adverse consequences have been linked convincingly to such
ultra low remodeling rates. In the absence of a clear relationship of low bone remodeling
rate to adverse outcomes, we feel that it is difficult to define a specific value for rate of bone
remodeling that can be considered “oversuppression.” That being said, we further believe
that the detection of a low remodeling state is problematic, given the tools available for
judging remodeling rates. As we have stated, while transilial bone biopsy-based
histomorphometry can be used to detect a range of bone remodeling activity, when BFR/BS
and Ac.f are reported as zero, the correct interpretation is that remodeling is low, but not
necessarily, or not even likely, zero, anywhere in either the specimen or the skeleton.
Furthermore, individuals who have BFR/BS and Ac.f reported as zero tend to display a
range of bone biochemical marker values from normal to low. Importantly, the biochemical
marker values rarely or never reach zero.
One method of analysis that can be used when there are no fluorochrome labels in a biopsy
specimen is illustrated in Table 4. We have recommended that a finding of no double label
in the standard sampling areas of an individual patient always be taken as a certain signal of
a low remodeling state, but never be taken to mean that the patient completely lacks
remodeling. We have also recommended that the main method for presenting the data from
such patients in studies with multiple treatment groups, is that they be included for MS/BS
(value of zero) and BFR/BS (value of zero) when no label of any kind is found, but excluded
from other important calculations such as mineral apposition rate (MAR) and all others that
depend upon MAR, due to the inability to calculate MAR. Excluding non-double label
patients from calculations of central tendency, creates an inaccurate upward bias in the
group BFR/BS and Ac.f values (less likely for MAR because it is so constant), in groups
containing patients without double label.
There is a way to compensate partially for this bias. The number of patients in a group
excluded from MAR and BFR/BS calculation due to lack of double label can serve as a
useful index of group remodeling state. Based on published data [8,27], investigators can
and should determine whether a treatment group has more subjects without double label
than: a) any logical comparator group within the study, b) healthy premenopausal women
[8], and c) untreated post-menopausal osteoporotic women [27].
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In Table 4, we present group sizes and the minimum numbers of subjects who lack double
label in the test group to establish significant differences (P<.05 and P<.01). We also add a
comparison that uses typical group sizes for pre-clinical studies. When the difference is
significant, a significantly low remodeling state exists in the test group. We use a typical
group size of 30–32 for human osteoporosis studies. For example, it is of interest to know
whether a treated group has lower bone formation rate than healthy pre-menopausal women.
If three subjects have no double label, remodeling rate is likely to be significantly lower than
in premenopausal women (P<.05). If five subjects lack double label, remodeling rate is even
more likely to be significantly lower than in premenopausal women (P<.01). We use the
group sizes presented [8,27] for the published data. This analysis was done with the Chi
Square test, and can be performed similarly for any comparator group size.
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Fig. 1.
Photomicrograph is displayed from a section 6 μm in thickness from one level of a transilial
biopsy specimen. The internal and external cortices and the intervening trabecular region
(~10× magnification) are apparent. Modified Goldner staining has been completed. Black
lines delineate a typical standard analysis region with dimensions ~4 mm (horizontal) by 5.5
mm (vertical). Note that the transitional zone adjacent to each cortex is excluded by the
vertical lines. Similarly, the periphery of the core that may include tissue damaged by the
wall of the trephine is excluded by the horizontal lines. All trabecular tissue inside the lines
is evaluated. Most microscope data (Table 1) are collected from a Goldner or similarly
stained slide. A very similar analysis region from the unstained section is outlined and
measured only for dL.Pm, sL.Pm, dL.N, sL.N, B.Pm, iL.Wi, and N.iL.Wi.
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Table 1
Measured variables.
Variable Units Symbol Definition
Trabecular region
Tissue area measured mm2 Tt.Ar Total trabecular tissue area of sections examined
Bone area mm2 B.Ar Total area of trabecular bone silhouettes examined (includes osteoid)
Osteoid area mm2 O.Ar Total area of osteoid examined
Osteoid width μm O.Wi Average width of osteoid seams
Number of osteoid widths measured # N.O.Wi Number of osteoid width measurements
Bone perimeter mm B.Pm Total length of bone perimeter examined
Wall width μm W.Wi Average of osteon wall width measurements
Number of wall widths measured # N.W.Wi Number of wall width measurements
Double label perimeter mm dL.Pm Total length of double label perimeter examined
Single label perimeter mm sL.Pm Total length of single label perimeter examined
Osteoid perimeter mm O.Pm Total length of osteoid perimeter examined
Eroded perimeter mm E.Pm Total length of eroded (resorption) perimeter examined
Osteoclast perimeter mm Oc.Pm Total length of perimeter occupied by osteoclasts
Osteoblast perimeter mm Ob.Pm Total length of perimeter occupied by osteoblasts
Reversal perimetera mm Rv.Pm Total length of perimeter occupied by reversal surface
Fibrosis perimeter mm Fb.Pm Total length of perimeter occupied by fibrous surface
Osteoclast number mm Oc.N Total number of osteoclasts
Interlabel width μm iL.Wi Average width between labels
Number of interlabel widths measured # N.iL.Wi Number of interlabel width measurements
Double label number # dL.N Total number of discrete double labels examined
Single label number # sL.N Total number of discrete single labels examined
Erosion deptha μm E.D Average depth of active resorption lacunae
Number of erosion depths measureda # N.E.D Number of erosion depth measurements
Cortical regionsb
Cortex #1 width μm Ct1.Wi Total width of Cortex#1
Number of cortex #1 widths measured # N.Ct1.Wi Number of Cortex#1 width measurements
Cortex #1 area mm2 Ct1.Ar Total area occupied by Cortex#1
Cortex #1 pore area mm2 Ct1.Po.Ar Total area occupied by Cortex#1 pores
Cortex #2 width μm Ct2.Wi Total width of Cortex#2
Number of Cortex #2 widths measured # N.Ct2.Wi Number of Cortex#2 width measurements
Cortex #2 area mm2 Ct2.Ar Total Area occupied by Cortex#2
Cortex #2 Pore area mm2 Ct2.Po.Ar Total area occupied by Cortex#2 pores
a
Seldom-used, optional measurements.
b
Current recommendation is to record measurements of Cortex #1 (thicker one) and Cortex#2 (thinner one) separately.
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Table 2
Recommended variables to report.
Variables Units Symbol Definition/formula
Tissue area mm2 Tt.Ar Area of sections examined
Bone area mm2 B.Ar Area of trabecular silhouettes examined
Bone perimeter mm B.Pm Total length of perimeter examined
Bone volume % BV/TV Percent of marrow space occupied by bone=100*(B.Ar/Tt.Ar)
Osteoid volume (bone tissue
referent)
% OV/BV Percent of bone tissue occupied by osteoid=100*(O.Ar/B.Ar)
Osteoid thickness μm O.Th Average thickness of osteoid seams=(π*O.Wi)/(4*N.O.Wi)
Wall thickness μm W.Th Average thickness of osteons=(π*W.Wi)/(4*N.W.Wi)
Mineral apposition rate μm/d MAR Mineral apposition rate=(iL.Wi*π)/(d*4)/N.iL.Wi
Adjusted mineral appositional rate μm/d Aj.AR Mineral apposition rate adjusted for osteoid surface bearing
label=MAR*(MS/OS)/100
Osteoid surface % OS/BS Percent of bone surface occupied by osteoid=100*O.Pm/B.Pm
Osteoblast surface % Ob.S/BS Percent of bone surface occupied by osteoblasts=100*Ob.Pm/B.Pm
Double label surface % dLS/BS Percent of bone surface occupied by double label=100*dL.Pm/B.Pm
Single label surface % sLS/BS Percent of bone surface occupied by single label=100*sL.Pm/B.Pm
Mineralizing surface % MS/BS = 100*(dL.Pm+0.5 sL.Pm)/B.Pm
Eroded (resorptive) surface % ES/BS Percent of bone surface occupied by resorption surface=100*(E.Pm/B.Pm)
Osteoclast surface % Oc.S/BS Percent of bone surface occupied by osteoclasts=100*(Oc.Pm/B.Pm)
Percentage of osteoid mineralizing % MS/OS Percent of osteoid surface mineralizing=100*(MS/BS)/(OS/BS)
Mineralization lag time d Mlt Average time lag for mineralization of osteoid=(O.Th*OS/BS)/(MAR*MS/
BS)
Osteoid maturation time d Omt Time for mineralization of osteoid at forming sites=O.Th/MAR
Bone formation rate (bone surface
ref.)
μm3/μm2/year BFR/BS Rate of bone formation, surface referent=MAR*MS/BS*365.25
Bone formation rate (bone volume
ref.)
%/year BFR/BV Rate of bone formation (bone volume referent)=((BS/TV)*(MS/
BS)*MAR*365.25 *100)/(BV/TV)*0.01
Activation frequency #/year Ac.f Frequency of appearance of new remodeling units at one location=(BFR/
BS)/W.Th*0.001
Cortical thickness #1 μm Ct1.Th Thickness of Cortex#1=Ct1.Wi/N.Ct1.Wi
Cortical porosity #1 % Ct1.Th Porosity of Cortex#1=100*Ct1.Po.Ar/Ct1.Ar
Cortical thickness #2 μm Ct2.Th Thickness of Cortex#2=Ct2.Wi/N.Ct2.Wi
Cortical porosity #2 % Ct2.Th Porosity of Cortex#2=100*Ct2.Po.Ar/Ct2.Ar
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Table 3
Variables that may be reported.
Variables Units Symbol Definition/formula
Surface density mm2/mm3 BS/TV Surface to volume ratio=Tt.Pm/Tt.Ar
Osteoblast number #/mm Ob.N/B.Pm Number of osteoblasts seen per mm in standard sections
Osteoclast number #/mm Oc.N/B.Pm Number of osteoclasts seen per mm in standard sections
Trabecular thickness μ Tb.Th Average thickness of trabeculae=(BV/TV)*20/(BS/TV)
Trabecular number #/mm Tb.N Number of trabecular silhouettes=(BV/TV)*10/Tb.Th
Trabecular separation μ Tb.Sp Average distance between trabeculae=(1000/TbN)−(Tb.Th/10)
Erosion depth μ E.D Erosion depth=E.D
Reversal surface % RvS/BS Percent trabecular bone in reversal phase=(RvPm/B.Pm)*100
Trabecular fibrosis surface % Fb.S/BS Percent trabecular bone with fibrous surface=(Fb.Pm/B.Pm)*100
Formation period d FP Average osteon formation period=(W.Th*OS/BS)/(MS/BS*MAR)
Resorption period d Rs.P Average osteon resorption period=(FP*ES/BS)/OS/BS
Remodeling period d Rm.P Average osteon remodeling period=FP+Rs.P
Bone formation Rate (total volume
ref.)
%/year BFR/TV Rate of bone formation, total volume referent=(MAR*365.25 *(T.Pm/
Tt.Ar))/0.01
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